Reata Sells Asian Rights to CKD Drug, But Plans To Remain A Solo Act In U.S.

Reata Pharmaceuticals on Jan. 7 licensed to Kyowa Hakko Kirin the Asian rights to its lead drug candidate, bardoxolone methyl, which a few years ago Reata re-directed from oncology to chronic kidney disease